Integrated Microsystems for Biosensing.

This program focuses on the development of microsystems-based devices for biosensing. An integrated approach will be followed, creating appropriately functionalized hardware via advanced microsystems technology, biofunctionalization of surfaces and development of specific diagnostic tools based on modern microbiological and biomedical insights. Cluster 1 aims at the detection of biomarkers that are characteristic for inflammatory diseases. The rationale behind this is that airway infections are the most prevalent class of infections in the Netherlands. Faster and more specific and more sensitive detection will assist adequate and early diagnosis of inflammatory diseases, which will greatly benefit the patient and reduce overall impact and costs of these diseases. The R&D program will allow the electrical detection of individual biomarker molecules, based on the specific biomarker  receptor/antibody interaction. Cluster 2 aims at the development of microsystems-based lab-on-a-chip systems for the improved (more sensitive and faster) detection of microbial pathogens. It will focus on pathogens present in sputum breath, serum and urine from patients with pulmonary diseases, such as tuberculosis and pneumonia. With the devices under study patients can be screened for pathogens in a direct way, providing results within an hour, while this currently takes up to many days.

Within this program, Innosieve will focus on the development of microsieve-based diagnostics for detection of clinically important pathogens in body fluids.

Large emphasis will be put on the sample pre‐treatment of urine and plasma to allow (fractional) microfiltration and the subsequent non‐destructive and quantitative detection of four clinically important bacterial pathogens, likely Staphylococcus aureus, Streptococcus pneumoniae, E.coli and Pseudomonas aeruginosa. The efficiency and reliability of both filtration and detection will be assessed by determining the sensitivity, specificity, accuracy and precision with a extended set of clinical plasma and urine samples. To ensure a diagnostic multiplex platform for the detection of clinically important human pathogens Innosieve will strongly interact with Aquamarijn and Wageningen University (bio-functionalization of surfaces) and CCM (development of a dedicated analyzer for array‐like microsieve platforms)